ClinicalTrials.gg
CompletedNCT06263244SPIDERUpdated Nov 6, 2026

Specifying the Anti-inflammatory Effects of Ziltivekimab

A Phase 3 interventional study of Ziltivekimab and Placebo in Atherosclerosis and Inflammation, sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA). Completed at 1 site in Netherlands. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Phase 3, Interventional, and Prevention

How we know

Updated Nov 6, 2026Now CompletedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
50 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 102 studies in Atherosclerosis with a site in Netherlands — 15 open to participants now, 24 under way, 9 of them phase 3. Atherosclerosis · Netherlands.

Enrollment
60th of 72
40 · median 274
Started
2024
with 4 others
Phase 3
21 of 102
2 open now
Registered
85th of 102
by date
Lead sponsor
8 of 102
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Among the 102 studies in Atherosclerosis with a site in Netherlands, this one is the 60th largest by enrollment of the 72 interventional ones that give a count, is one of 5 that started in 2024, is one of 21 in phase 3, and was the 85th registered.

Atherosclerosis

1,519 studies on the registry are indexed under Atherosclerosis; 226 are open to participants now.

Browse Atherosclerosis studies →

Open to participants now

15 of the 102 studies in Atherosclerosis with a site in Netherlands are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 164 Atherosclerosis studies recruiting now, 86 (52%) set no upper age limit and 34 (21%) stop at 75 or younger; 16 take children under 18; 35 take healthy volunteers.

This study: 50 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 102 studies in Atherosclerosis with a site in Netherlands, or all of them as a file.
02

Study summary

The goal of this randomized, double blind, placebo controlled trial is to study whether ziltivekimab therapy reduces arterial wall inflammation as assessed by imaging, and reduces the systemic inflammatory tone as assessed by circulating monocytes, inflammatory biomarkers and proteomics.

Read the detailed description

Considering that ziltivekimab is currently undergoing a phase 3 CVOT trial, it is of great importance to elucidate its mechanistic effects. The objective of this study is to research whether ziltivekimab therapy for 20 weeks reduces arterial wall inflammation, as assessed by state-of-the-art imaging modalities, and reduces systemic inflammatory tone, as assessed by in depth phenotyping of circulating monocytes, inflammatory biomarkers and proteomics. The imaging modalities used in this study are 68Ga-DOTATATE PET/CT and CCTA. This study is designed as a single center, randomized, double-blinded, placebo-controlled intervention study in 40 atherosclerotic patients of 50 years and older with hsCRP levels of 2 mg/L and above.

03

Conditions studied

  • Atherosclerosis
  • Inflammation

Keywords

  • DOTATATE
  • Ziltivekimab
  • Inflammation
  • Monocytes
  • CCTA
  • PET/CT
04

Who can participate

Ages eligible
50 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 50 years and older.
  • Multi-vessel coronary artery disease (defined as CAD-RADS ≥2).
  • Serum hsCRP level ≥2 mg/L.

Exclusion criteria

Exclusion Criteria:

  • Coronary stents in situ.
  • Chronic or recent (\<1 month) (serious) infections and/or clinical signs of acute (serious) infection.
  • History of severe auto-immune diseases, or other (severe) (recurrent or chronic) inflammatory disorders.
  • Use of preventive systemic antibiotics (antibiotics used to treat latent tuberculosis are exempted).
  • Stable lipid lowering treatment for less than 4 weeks, including statins, ezetimibe and PCSK9 inhibition.
  • Untreated latent tuberculosis, active (positive HBsAg and/or positive anti-HBc with detectable HBV DNA) or C, (HIV) not on stable antiretroviral regimen
  • Uncontrolled diabetes ( >90 mmol/mol).
  • Renal insufficiency, defined as \<45 ml/min/1.73 m2.
  • count \<120,000 and >450,000 /mm3.
  • Elevated liver enzymes (>3 of liver transaminases), acute liver failure or known (severe) liver disease.
  • Premenopausal women not using birth-control.
  • History of gastrointestinal perforation, active diverticulitis (within 5 years) or active inflammatory bowel disease (within 12 months).
  • Uncontrolled hypertension (systolic >180 mmHg; diastolic >110 mmHg).
  • Diagnosis of (active) in last 5 years.
  • Standard to 68Ga-DOTATATE PET, and CT based on physician's experience and current practices.
  • Inability or unwillingness to comply with the protocol requirements, or deemed by investigator to be unfit for the study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Ziltivekimab

    15 mg ziltivekimab subcutaneously once per month for 5 months

    Drug: Ziltivekimab

  • Placebo comparator
    Placebo

    Placebo, subcutaneously, once per month for 5 months

    Drug: Placebo

Interventions

  • Monoclonal antibody targeting IL-6

    Also known as: no other intervention name

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. TBRmax coronary arteries

    mean percentage change in coronary arteries target to background ratio (TBRmax)

    Time frame: 5.5 months

  2. monocyte activation marker protein expression

    The impact of ziltivekimab on a mass cytometry monocyte phenotype panel; expression markers such as CD14 and CD16.

    Time frame: 5.5 months

Secondary outcomes

  1. delta PCAT

    Difference in PCAT (CCTA derived) after ziltivekimab treatment.

    Time frame: 5.5 months

  2. Correlation delta TBRmax and CCTA derived plaque characteristics

    Correlation between changes in coronary 68Ga-DOTATATE uptake and anatomical plaque changes on CCTA.

    Time frame: 5.5 months

  3. delta SUVmax bone marrow

    Difference in 68Ga-DOTATATE SUVmax of bone marrow after treatment.

    Time frame: 5.5 months

  4. delta TBRmax ascending aorta

    Difference in 68Ga-DOTATATE TBRmax of ascending aorta after treatment

    Time frame: 5.5 months

  5. changes monocyte phenotype

    The impact of ziltivekimab on monocyte phenotype in transendothelial migration (TEM) capacity and transcriptome profile.

    Time frame: 5.5 months

  6. changes in hsCRP

    hsCRP (high-sensitivity C-reactive protein): mg/L

    Time frame: 5.5 months

  7. changes plasma cytokine and chemokine levels (pg/mL)

    TNF-α (Tumor Necrosis Factor alpha): pg/mL IL-8 (Interleukin-8): pg/mL MCP-1 (Monocyte Chemoattractant Protein-1): pg/mL

    Time frame: 5.5 months

  8. changes plasma cytokine and chemokine levels (ng/mL)

    sICAM (soluble Intercellular Adhesion Molecule): ng/mL sVCAM (soluble Vascular Cell Adhesion Molecule): ng/mL

    Time frame: 5.5 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2024 to primary completion in Oct 2026, 29 months.

Of 54 phase 3 interventional studies under Atherosclerosis, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 63. This study's 29 months is below that.

Primary completion moved once since we started tracking on Sep 25, 2026: Sep 2026 → Oct 2026, on Nov 6, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2023
First posted
Feb 16, 2024
StartActual
May 3, 2024
Primary completionActual
Oct 30, 2026was Sep 2026
CompletionActual
Oct 30, 2026
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 6, 2026
Primary completion
Sep 4, 2026→Oct 30, 2026 (actual)
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Active, not recruiting→Completed
    Primary completion Sep 4, 2026→Oct 30, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06263244
Responsible party
E.S.stroes (Prof. dr. E.S.G. Stroes, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)) — Principal investigator
First posted
Feb 16, 2024
Start date
May 3, 2024
Primary completion
Oct 30, 2026
Completion
Oct 30, 2026
Last update
Nov 6, 2026

Study contacts

E.S.G. Stroes, Prof.dr.
principal investigator · Amsterdam UMC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ziltivekimab

Start the discussion